ATROPINE JUNO atropine sulfate monohydrate 1.2mg/1mL injection BP ampoule

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

atropine sulfate monohydrate, Quantity: 1.2 mg/mL

Commercializzato da:

Juno Pharmaceuticals Pty Ltd

Forma farmaceutica:

Injection, solution

Composizione:

Excipient Ingredients: sodium chloride; water for injections; hydrochloric acid

Via di somministrazione:

Intramuscular, Intravenous, Subcutaneous

Confezione:

1mL x 50

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

INDICATIONS AS AT 30 SEPTEMBER 2003 : Surgery: Atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. After surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. Cardiopulmonary resuscitation: Atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. Anticholinesterase Poisoning: Atropine sulfate is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, Amanita muscaria mushrooms or other compounds with anticholinesterase activity. A cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Dettagli prodotto:

Visual Identification: Clear, colourless, particle-free solution.; Container Type: Ampoule; Container Material: PE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2022-07-01